Toshiki Mizuno

Summary

Affiliation: Kyoto Prefectural University of Medicine
Country: Japan

Publications

  1. request reprint
    Mizuno T, Takanashi Y, Onodera H, Shigeta M, Tanaka N, Yuya H, et al. A case of lymphomatoid granulomatosis/angiocentric immunoproliferative lesion with long clinical course and diffuse brain involvement. J Neurol Sci. 2003;213:67-76 pubmed
    ..Cyclophosphamide was effective and there has been no recurrence of symptoms in the last 5 years. We reviewed the non-tumorous LYG/AIL involving the CNS, and discussed the clinical features, MRI imaging and diagnosis of the LYG/AIL...
  2. request reprint
    Mizuno T, Muranishi M, Torugun T, Tango H, Nagakane Y, Kudeken T, et al. Two Japanese CADASIL families exhibiting Notch3 mutation R75P not involving cysteine residue. Intern Med. 2008;47:2067-72 pubmed
    ..These families provide new insights into the diagnosis and pathomechanisms of CADASIL. ..
  3. Mizuno T, Kondo M, Ishigami N, Tamura A, Itsukage M, Koizumi H, et al. Cognitive impairment and cerebral hypoperfusion in a CADASIL patient improved during administration of lomerizine. Clin Neuropharmacol. 2009;32:113-6 pubmed publisher
    ..Cognitive decline and cerebral hypoperfusion improved during 2-year administration of lomerizine in this CADASIL patient, and thus, lomerizine is a potential candidate for treating cognitive impairment in CADASIL patients...
  4. Mizuta I, Watanabe Hosomi A, Koizumi T, Mukai M, Hamano A, Tomii Y, et al. New diagnostic criteria for cerebral autosomal dominant arteriopathy with subcortical infarcts and leukocencephalopathy in Japan. J Neurol Sci. 2017;381:62-67 pubmed publisher
    ..We aimed to develop criteria for selecting patients suspected for CADASIL to undergo genetic testing...

Locale

Detail Information

Publications4

  1. request reprint
    Mizuno T, Takanashi Y, Onodera H, Shigeta M, Tanaka N, Yuya H, et al. A case of lymphomatoid granulomatosis/angiocentric immunoproliferative lesion with long clinical course and diffuse brain involvement. J Neurol Sci. 2003;213:67-76 pubmed
    ..Cyclophosphamide was effective and there has been no recurrence of symptoms in the last 5 years. We reviewed the non-tumorous LYG/AIL involving the CNS, and discussed the clinical features, MRI imaging and diagnosis of the LYG/AIL...
  2. request reprint
    Mizuno T, Muranishi M, Torugun T, Tango H, Nagakane Y, Kudeken T, et al. Two Japanese CADASIL families exhibiting Notch3 mutation R75P not involving cysteine residue. Intern Med. 2008;47:2067-72 pubmed
    ..These families provide new insights into the diagnosis and pathomechanisms of CADASIL. ..
  3. Mizuno T, Kondo M, Ishigami N, Tamura A, Itsukage M, Koizumi H, et al. Cognitive impairment and cerebral hypoperfusion in a CADASIL patient improved during administration of lomerizine. Clin Neuropharmacol. 2009;32:113-6 pubmed publisher
    ..Cognitive decline and cerebral hypoperfusion improved during 2-year administration of lomerizine in this CADASIL patient, and thus, lomerizine is a potential candidate for treating cognitive impairment in CADASIL patients...
  4. Mizuta I, Watanabe Hosomi A, Koizumi T, Mukai M, Hamano A, Tomii Y, et al. New diagnostic criteria for cerebral autosomal dominant arteriopathy with subcortical infarcts and leukocencephalopathy in Japan. J Neurol Sci. 2017;381:62-67 pubmed publisher
    ..We aimed to develop criteria for selecting patients suspected for CADASIL to undergo genetic testing...